1. Home
  2. CERT vs SPTX Comparison

CERT vs SPTX Comparison

Compare CERT & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Certara Inc.

CERT

Certara Inc.

HOLD

Current Price

$8.42

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Logo Seaport Therapeutics Inc. Common Stock

SPTX

Seaport Therapeutics Inc. Common Stock

N/A

Current Price

$24.25

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CERT
SPTX
Founded
2008
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
2020
2026

Fundamental Metrics

Financial Performance
Metric
CERT
SPTX
Price
$8.42
$24.25
Analyst Decision
Buy
Analyst Count
10
0
Target Price
$11.67
N/A
AVG Volume (30 Days)
3.7M
106.4K
Earning Date
05-11-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
87.50
N/A
EPS
N/A
N/A
Revenue
$418,838,000.00
N/A
Revenue This Year
$4.18
N/A
Revenue Next Year
$5.39
N/A
P/E Ratio
N/A
N/A
Revenue Growth
8.75
N/A
52 Week Low
$4.45
$17.59
52 Week High
$13.88
$26.32

Technical Indicators

Market Signals
Indicator
CERT
SPTX
Relative Strength Index (RSI) 63.31 65.81
Support Level $7.94 $18.72
Resistance Level $9.93 N/A
Average True Range (ATR) 0.37 1.44
MACD -0.01 0.09
Stochastic Oscillator 83.04 70.22

Price Performance

Historical Comparison
CERT
SPTX

About CERT Certara Inc.

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.

About SPTX Seaport Therapeutics Inc. Common Stock

Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.

Share on Social Networks: